source
- Celcuity waits on FDA review of second plant as cancer drug rollout lags expectationsCelcuity has announced that it is awaiting the U.S. Food and Drug Administration’s review of a second manufacturing facility needed for its newly approved cancer therapy. The company explained tha…
- Slate Medicines to merge with Fulcrum Therapeutics after Fulcrum drops sickle-cell drugSlate Medicines announced it will combine with Fulcrum Therapeutics in a reverse merger, giving the struggling biotech a new corporate home. Fulcrum had been developing pociredir, a therapy design…